Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sara A Byron

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
Plos One|October 12, 2012
Negative regulation of NF-κB by the ING4 tumor suppressor in breast cancerSara A Byron, Elizabeth Min, Tanya S Thal, et al.
Plos One|June 7, 2017
A prospective pilot study of genome-wide exome and transcriptome profiling in patients with small cell lung cancer progressing after first-line therapyGlen J Weiss, Sara A Byron, Jessica Aldrich, et al.
Cancer Research|September 2, 2008
Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogationSara A Byron, Michael G Gartside, Candice L Wellens, et al.
Neoplasia (New York, N.Y.)|August 3, 2013
The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitorsSara A Byron, Huaibin Chen, Andreas Wortmann, et al.
Molecular Oncology|December 12, 2018
Bcl-2 inhibitors enhance FGFR inhibitor-induced mitochondrial-dependent cell death in FGFR2-mutant endometrial cancerLeisl M Packer, Samantha J Stehbens, Vanessa F Bonazzi, et al.
Veterinary and Comparative Oncology|May 30, 2023
Standing in the canine precision medicine knowledge gap: Improving annotation of canine cancer genomic biomarkers through systematic comparative analysis of human cancer mutations in COSMICSharadha Sakthikumar, Salvatore Facista, Derick Whitley, et al.
Journal of Pediatric Hematology/Oncology|November 11, 2024
Retrospective Comparison of Targeted Anticancer Drugs Predicted by the CNS-TAP Tool Versus Those Selected by a Molecularly Driven Tumor Board in Children With DIPGHolly J Roberts, Karthik Ravi, Bernard L Marini, et al.
Plos One|March 19, 2016
Insulin Receptor Substrate Adaptor Proteins Mediate Prognostic Gene Expression Profiles in Breast CancerMarc A Becker, Yasir H Ibrahim, Annabell S Oh, et al.
Molecular and Cellular Biology|July 1, 2009
Homodimerization controls the fibroblast growth factor 9 subfamily's receptor binding and heparan sulfate-dependent diffusion in the extracellular matrixJuliya Kalinina, Sara A Byron, Helen P Makarenkova, et al.
Frontiers in Oncology|April 6, 2019
Leveraging Spatial Variation in Tumor Purity for Improved Somatic Variant Calling of Archival Tumor Only SamplesRebecca F Halperin, Winnie S Liang, Sidharth Kulkarni, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
Plos One|October 12, 2012
Negative regulation of NF-κB by the ING4 tumor suppressor in breast cancerSara A Byron, Elizabeth Min, Tanya S Thal, et al.
Plos One|June 7, 2017
A prospective pilot study of genome-wide exome and transcriptome profiling in patients with small cell lung cancer progressing after first-line therapyGlen J Weiss, Sara A Byron, Jessica Aldrich, et al.
Cancer Research|September 2, 2008
Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogationSara A Byron, Michael G Gartside, Candice L Wellens, et al.
Neoplasia (New York, N.Y.)|August 3, 2013
The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitorsSara A Byron, Huaibin Chen, Andreas Wortmann, et al.
Molecular Oncology|December 12, 2018
Bcl-2 inhibitors enhance FGFR inhibitor-induced mitochondrial-dependent cell death in FGFR2-mutant endometrial cancerLeisl M Packer, Samantha J Stehbens, Vanessa F Bonazzi, et al.
Veterinary and Comparative Oncology|May 30, 2023
Standing in the canine precision medicine knowledge gap: Improving annotation of canine cancer genomic biomarkers through systematic comparative analysis of human cancer mutations in COSMICSharadha Sakthikumar, Salvatore Facista, Derick Whitley, et al.
Journal of Pediatric Hematology/Oncology|November 11, 2024
Retrospective Comparison of Targeted Anticancer Drugs Predicted by the CNS-TAP Tool Versus Those Selected by a Molecularly Driven Tumor Board in Children With DIPGHolly J Roberts, Karthik Ravi, Bernard L Marini, et al.
Plos One|March 19, 2016
Insulin Receptor Substrate Adaptor Proteins Mediate Prognostic Gene Expression Profiles in Breast CancerMarc A Becker, Yasir H Ibrahim, Annabell S Oh, et al.
Molecular and Cellular Biology|July 1, 2009
Homodimerization controls the fibroblast growth factor 9 subfamily's receptor binding and heparan sulfate-dependent diffusion in the extracellular matrixJuliya Kalinina, Sara A Byron, Helen P Makarenkova, et al.
Frontiers in Oncology|April 6, 2019
Leveraging Spatial Variation in Tumor Purity for Improved Somatic Variant Calling of Archival Tumor Only SamplesRebecca F Halperin, Winnie S Liang, Sidharth Kulkarni, et al.
Pageof 4